Can a fingerprint scan replace traditional drug tests?
NCT ID NCT07758777
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial evaluates how easy and effective the Intelligent Fingerprinting Drug Screening System is to use in a clinic. It involves 45 healthy adults: 15 operators who are trained to use the system and 30 donors who provide samples. The study focuses on whether operators can successfully complete a 20-step procedure after training, with each session lasting 2-4 hours.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Intelligent Fingerprinting Drug Screening System
- What this could lead to
- If successful, this could support the system's use as a quick, non-invasive way to screen for drug use in clinics and other settings.
- What could go wrong
- This is a small usability study, not a test of accuracy or effectiveness. Results may not reflect real-world performance or apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
45 people
The number who actually took part.
- Started
-
Jul 2026
- Finished
-
Jul 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Informed of the nature of the study, agreed to, and able to read, review, and sign the informed consent document prior to dosing. The informed consent document will be written in English; therefore, the subject must have the ability to read and communicate in English. 2. Completed the screening process within 30 days prior to enrollment. Subjects screened as a part of an IRB-approved General Screening Protocol at the clinical research site may be included in this study without additional screening procedures provided all the required screening procedures have been performed within 30 days prior to enrollment. Exclusion Criteria: 1. Is not able to read and communicate in English. 2. If, in the opinion of the Investigator, the subject is not suitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adult participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExel HRI
Marlton, New Jersey, 08053, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nicotine pouches put to the test: can they match the cigarette experience?
- Can a neck device dial down pain by zapping the vagus nerve?
- Tight calves may dull the Sole's sense of touch
- Can a migraine pill sway the Body's balance reflex?
- Can an experimental drug share the Body's chemical highways without causing a pileup?
- Can dirty city air speed up the Body's aging clock?